This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by Imperial College London.
Recruitment status was:  Not yet recruiting
Information provided by:
Imperial College London Identifier:
First received: September 13, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
Does the addition of steroids during the first trimester to the standard aspirin + heparin treatment reduce the miscarriage rates in women with antiphospholipid antibodies and recurrent first trimester miscarriage in those who had an unsuccessful pregnancy with aspirin + heparin?

Condition Intervention Phase
Antiphospholipid Syndrome Drug: Low dose steroids Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomised Controlled Trial of Low Dose Steroid +Aspirin +Heparin Versus Aspirin+Heparin Amongst Pregnant Women With APS

Resource links provided by NLM:

Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • Successful pregnancy outcome

Estimated Enrollment: 90
Study Start Date: October 2005
Detailed Description:
Over the last decade, the APS has emerged as most important treatable cause of recurrent miscarriages. The pathogenesis of fetal loss in this condition is still remains obscure. Despite the success of aspirin + heparin treatment, some pregnant women with APS repeatedly miscarry even on treatment. The trial is designed to determine if addition of steroids has an success in these women. This is in view of recent in vitro data from our unit reporting that there is an increase decidual cytokine response in APS positive women.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

History of 3 or more consecutive miscarriages and positive antiphospholipid antibodies on at least two occasions more than 6 weeks apart before becoming pregnant and an unsuccessful pregnancy with aspirin + heparin with a karyotype of miscarriage either unavailable or normal (46XX/ 46XY).

Exclusion Criteria:

Abnormal karyotype of women or partner, previous thromboembolism, SLE, diabetes mellitus, hypertension, sensitivity to aspirin, heparin and prednisolone, multiple pregnancy.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00180778

Contact: Lesley Regan, FRCOG 02078861050

United Kingdom
St. Mary's Hospital Not yet recruiting
London, United Kingdom, W2 1NY
Contact: Lesley Regan, FRCOG    02078861050   
Sponsors and Collaborators
Imperial College London
Principal Investigator: Raj Rai, MRCOG Imperial College London
  More Information Identifier: NCT00180778     History of Changes
Other Study ID Numbers: 05/Q0403/155
Study First Received: September 13, 2005
Last Updated: September 13, 2005

Additional relevant MeSH terms:
Antiphospholipid Syndrome
Pathologic Processes
Autoimmune Diseases
Immune System Diseases processed this record on September 21, 2017